Background
Molecular studies have determined that aberrant signaling in the mitogen-activated protein kinase (MAPK) signaling cascade (Raf-MEK1/2-ERK1/2) is a crucial step in melanocytic neoplasia, ultimately deregulating the activity of key transcription factors that control cell growth, differentiation, and survival [
1]. Specifically, gain of function mutations in which the 600 valine residue of the BRAF kinase is substituted with glutamic acid (BRAF
V600E) are present in ~40 % of patients presenting with malignant melanoma [
2]. Survival is enhanced if detection, treatment and surgical excision occur when the tumor burden is restricted to a primary site; however, once the disease has metastasized to distant organs such as the lung, brain, bone, and liver, prognosis is poor, with a median survival of ~ 9 months [
3]. These dismal statistics are in part due to the intrinsic resistance of melanoma to platinum-based chemotherapeutics and its rapid acquisition of resistance to initial therapeutic interventions [
4,
5]. Present treatment strategies involve small molecule inhibitors of this mutant BRAF kinase, such as vemurafenib and dabrafenib [
6,
7]. However, these therapies are only effective in a subset of patients: those that harbor the more prevalent BRAF
V600E and the less common BRAF
V600K mutations [
8]. While drugs targeting this specific isoform are among the most promising melanoma treatments, patients eventually relapse due to reactivation of the MAPK signaling cascade, specifically ERK activity [
5,
9]. To overcome
de novo resistance, a combinatorial treatment of vemurafenib with a MEK inhibitor is administered in an effort to combat reactivation of the MAPK pathway [
10‐
12]. However, mechanisms that underlie acquired resistance after treatment with multiple inhibitors of this pathway remain elusive.
Drug resistance has been shown to be mediated by tissue architecture and cell-adhesion [
13,
14]. In particular, cell adhesion-mediated drug resistance (CAM-DR) is an emergent phenotype associated with cell-cell adhesion or 2D adhesion to extracellular matrices. Myeloma cells cultured as monolayers that had adhered to fibronectin were resistant via upregulation of α4 β1 integrin compared to cells treated in suspension [
15]. Similarly, tumor cells grown as spheroids show increased resistance to therapy compared to the same cells that are dissociated and grown as monolayers [
16]. However, the observed acquired drug resistance following multiple targeting of the MAPK pathway is not readily explained by CAM-DR [
12]. Because this reactivation attenuates drug response, it may also contribute to the development of acquired resistance [
12].
The tumor microenvironment is emerging as a critical factor in malignant progression, metastasis and tumor etiology [
17,
18]. To explore mechanisms that drive tumors to overcome and survive under unfavorable conditions, we aimed to delineate tumor-induced microenvironmental responses to the stress induced by drug therapeutics. Tumor cells actively modulate the host environment by secreting cytokines that reprogram stromal cells to change the extracellular matrix (ECM) milieu, thus creating a
de novo microenvironment [
17,
18]. While immunotherapy and monoclonal antibodies targeting tumor angiogenesis have shown promising results, many microenvironmental targets remain underexplored [
18]. For example, overexpression of secreted ECM proteins such as fibronectin (FN) has been found in several solid carcinomas, and postulated to be beneficial for tumor growth and instrumental in the establishment of an ideal microenvironment [
19]. Furthermore, heterogeneous expression of ECM components within tumors has been observed [
20]. Pathologists have long associated the presence of abundant ECM proteins in tumors with poor prognosis and an expected dismal response to therapeutic intervention [
21].
Recently, a study showed that non-small cell lung cancer cells induced FN biogenesis via p38 MAPK in response to treatment with cetuximab (targeting the EGF receptor upstream of the MAPK signaling pathway) [
22]. This response was found to blunt the cytotoxic effects of cetuximab and reduced sensitivity to radiotherapy in in vitro and in vivo murine models. FN biogenesis may also reduce the efficacy of drugs targeting the BRAF kinase. Earlier observations found that a cocoon of ECM proteins, including FN, laminin, collagen IV and Tenascin C, protect small lung cancer cells from chemotherapy-induced apoptosis [
23]. We hypothesized that melanoma cells modulate secretion of not only FN, but also other ECM molecules to survive drug treatment. An important question is whether baseline ECM expression per se can predict cell survival and drug resistance. Furthermore, is upregulation of ECM proteins a reaction to evolutionary pressure following drug treatment, the result of selection for pre-existing resistant subpopulations, or a combination of both? Seeking to identify and determine the temporal regulation of the secreted ECM proteins, we focused on two isogenic cell lines to mimic intratumoral heterogeneity. Our results indicate that tumor cells adjust their 3D microenvironment by modulating secretion of FN and Tenascin-C (TNC), thereby blunting the effects of MAPK pathway inhibition. We show that only clones that can modulate their ECM secretion in response to pharmaceutical stress survive. Mechanistically, FN biogenesis via p38 MAP kinase via β1 integrin is induced following pharmaceutical treatment of the MAPK signaling pathway. Also, our data suggests that biogenesis of TNC is an possible alternative to impaired FN production. This study indicates a critical role for
de novo ECM biogenesis as a mechanism driving acquired resistance to drugs targeting MAPK signaling in cutaneous melanoma.
Methods
Human melanoma cell lines, A375 (cat. No. CRL-1619) and A375.S2 (cat. No. CRL-1872) cells were obtained from American Type Culture Collection (ATCC, Manassas, VA) and cultured on tissue culture flasks as described by the ATCC. A375 and A375.S2 cells were grown as monolayers in DMEM high glucose media (Life Technologies, Carlsbad, CA) supplemented with final volume of 10 % Fetal Bovine Serum (FBS), 1 % MEM non-essential amino acids, L-Glutamine, Penicillin and Streptomycin. Cells cultured with the media was refreshed every 2-3 days.
Animal studies
Animal studies were conducted under protocols approved by the National Cancer Institute, and the National Institutes of Health Animal Care and Use Committee. Briefly, 5 × 105 A375 cells were injected via tail vein into 8–10-week old female nu/nu mice. Three weeks after injection mice were euthanized and lungs were extracted and inflated and fixed in 4 % paraformaldehyde solution for 12 h and then prepared for histological staining. Lungs were then embedded in paraffin prior to sectioning on a microtome. Following antigen retrieval using xylene, samples were rehydrated and serial sections; 8 μm thick were labeled for specific stains of human fibronectin and DAPI.
Human tissue arrays and RNAseq
Human tissue arrays (cat # T386) were purchased from US Biomax (US Biomax, Rockville, MD) where tissue biopsies of human normal skin, melanoma with and without metastasis were examined by immunofluorescence. Briefly, antigen retrieval using xylene as described for mouse tissue was conducted and following re-hydration. Samples were stained for human Fibronectin and DAPI. Public RNAseq datasets were submitted to National Center for Biotechnology Information (NCBI) and examined for expression of extracellular matrix proteins [
24] and a search was done for public studies that involved ECM in melanoma (
http://www.ncbi.nlm.nih.gov/pubmed/?term=tenascin%20C%20AND%20melanoma). Briefly, normal melanocyte cell lines were compared to melanoma cell lines. In addition, data before and after treatment in human patients were also mined from publicly available databases.
3D cell culture
Cells were seeded at a concentration of 2 × 10
5 cells per ml of Matrigel (BD Biosciences, San Jose, CA), which polymerized to form a hydrogel at 37 °C. Media was added to the hydrogels after 30 min to ensure complete gelation. Cells were harvested after growth in 2D and embedded in laminin-rich extra cellular matrix (lrECM) (BD Biosciences) at 37 °C, in 5 % CO
2 as previously described [
25]. Clonally derived multicellular aggregates were examined 10 days later for morphology and protein analysis.
For 2D culture, cells were seeded at 5 × 10
5 cells per well in a six well plate with regular media. After 24 h the regular media was removed and cells were washed twice with PBS, and serum-free media was added. Conditioned (serum-free) media and cell lysate were collected after 24 h. For 3D culture, cell washing and refresh with conditioned medium was conducted repeated at day 8, following sample collection at day 9. For 3D cultures, cells were also harvested from lrECM for immunoprecipitation as previously described [
25]. Melanoma cells and normal human melanocytes were lysed in Mammalian Protein Extraction Reagent (Thermo Scientific, Waltham, MA), 1× protease inhibitor cocktail (Calbiochem, Billerica, MA) and 1× phosphatase inhibitor cocktail 2 & 3 (Sigma-Aldrich, St. Louis, MO) followed by centrifugation (13,200 rpm, 4 °C, 5 min), after which the supernatants were stored at -80 °C until use. Protein concentrations were determined with the Pierce
® BCA Protein Assay kit (Thermo Scientific), using BSA as the concentration standard. Extracted proteins were then resolved using 4–12 % Bis-Tris Gels (Life Technologies) and subsequently transferred to PVDF membranes (Life Technologies) for immunoblotting.
Western blot analysis
PVDF membranes were washed and blocked with 1 % BSA in TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.4) containing 0.1 % Tween-20 (TBS-T) and incubated with the primary antibodies. Next, the membranes were incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG (GE Healthcare, Buckinghamshire, UK) or sheep anti-mouse IgG (GE Healthcare). Finally, the immunoblot was incubated with an enhanced chemiluminescence (ECL) reaction system (Invitrogen) and the ECL signals were visualized by film. The antibodies were used at the following dilutions: anti-FN (1:1,000), anti-αv integrin (1:1,000), anti-β1 integrin (1:1,000), anti-phospho-p44/42MAPK (1:1,000), anti-p44/42MAPK (1:1,000), and anti-GAPDH (1:2,000). Except anti-FN (Origene, Rockville, MD), antibodies are purchased from Cell Signaling Technology (Danvers, MA).
Total RNA was extracted using an RNeasy mini Kit (Qiagen, Valencia, CA) and first-strand complementary DNAs (cDNAs) were synthesized from 500 ng of each total RNA preparation with the Quantitect Reverse Transcription kit (Qiagen) according to the manufacturers’ instructions. The PCR products were detected by SYBR Safe DNA gel stain (Invitrogen) after separation in 1 % agarose gel. β-actin was used as a housekeeping gene to evaluate and compare the quality of different cDNA samples. The primer sequences and the expected sizes of PCR products were as follows: Human FN 1, forward, 5’-ACAGGAAAGAGATGCGCCAA-3’, reverse, 5’-GGAAGAGTTTAGCGGGGTCC-3’ (403 bp); Human β-actin, forward, 5’-AGCCTCGCCTTTGCCGA-3’, reverse, 5’-CTGGTGCCTGGGGCG-3’ (174 bp). AmpliTaq Gold with GeneAmp and dNTP Mix (Applied Biosystems, Branchburg, NJ) were used for the RT-PCR analysis. We used a denaturing step of 94 °C for 5 min, followed by a cycling program of 94 °C for 10 s, 58 °C (Human FN1) or 60 °C (Human β-actin) for 60 s, and 72 °C for 60 s for 40 cycles, and a final holding stage at 4 °C.
Materials for mass spectroscopy
Dithiothreitol (DTT), acetonitrile (ACN), ammonium bicarbonate, trifluoretic acids (TFA), and iodoacetamide (IAA) were from Thermo Fisher Scientific. Trypsin Gold, mass spectrometry grade, was from Promega (Madison, WI). Nanopure water was prepared with use of Milli-Q water purification system (Millipore, Billerica, MA).
Preparation for in-gel protein digestion
For MS analysis, cells were grown in 1 % dialyzed FBS in 10 cm dishes and conditioned media (CM) collected every 2 days; protease and proteinase inhibitors were added immediately. CM was centrifuged at 3,500 rpm for 30 min to remove cell debris and the supernatant was concentrated using Amicon Ultra-15, Ultracel-3 K (ThermoFisher, Cat No: UFC900324) following the manufacturer’s instructions until the volume was reduced to ~300ul. Protein concentration was determined using BCA assay. 30 μg of proteins were separated using precast 4–20 % Tris-Glycine SDS-PAGE gels (Life Technologies). Total protein resolved in the polyacrylamide gel was stained with Coomassie blue (Sigma). The gel was destained, reduced, alkylated, and dried for in-gel digestion. Biological replicates at each time point (n = 3) were run on the same gel and processed simultaneously.
In-gel protein digestion
The dried gel pieces were rehydrated and digested in 80 μL of 12.5 ng/μL Trypsin Gold/50 mM ammonium bicarbonate at 37 °C overnight. After the digestion was complete, condensed evaporated water was collected from tube walls by 5 s centrifugation using a benchtop microcentrifuge (Eppendorf, Hauppauge, NY). The gel pieces and digestion reaction were mixed with 50 μL 2.5 % TFA and rigorously mixed for 15 min. The solution with extracted peptides was transferred into a fresh tube. The remaining peptides were extracted with 80 μL 70 % ACN/5 % TFA mixture using rigorous mixing for 15 min. The extracts were pooled and dried to completion (1.5–2 h) in SpeedVac. The dried peptides were reconstituted in 30 μL 0.1 % TFA by mixing for 5 min and stored in ice or at −20 °C prior analysis.
LC-MS/MS analysis
Samples were centrifuged at 14,000–16,000 × g for 10 min to remove particulate material. Five microliters of each sample were injected into a self-packed fused silica nano column, which had been pulled to a 5 μm i.d. tip using a P-2000 CO2 laser puller (Sutter Instruments, Novato, CA), then packed with 13 cm of 3 μm C18 reverse phase (RP) particles (Magic C18 AQ 3 μm (Michrom. Bioresources, Auburn, CA)) and equilibrated in 5 % acetonitrile, 0.1 % formic acid. Full MS spectra were recorded on the peptides over a 400 to 2000 m/z range by the Orbitrap, followed by five tandem mass (MS/MS) events sequentially generated by LTQ in a data-dependent manner on the first, second, third, and fourth most intense ions selected from the full MS spectrum (at 35 % collision energy). Mass spectrometer scan functions and HPLC solvent gradients were controlled by the Xcalibur data system (Thermo Finnigan, San Jose, CA).
Database search and interpretation of MS/MS datasets
Tandem mass spectra were searched against a concatenated target-decoy database containing the forward and reverse sequences of the target database using the Proteome Discoverer 1.4 and SEQUEST search engine (Thermo Finnigan). The target sequence was downloaded from a human Uniprot database (database released on November 13, 2013) and 124 common contaminant proteins. The search algorithm was configured to specify the following parameters: precursor tolerance, 10 ppm; fragment tolerance, 0.5 Da; static modification, cysteine carbamidomethylation; and fully tryptic status. SEQUEST search results from Proteome Discoverer were further analyzed by Scaffold (Proteome Software Inc., Portland, OR). The discriminant score was set such that a false positive rate of 1 % was determined based on the number of accepted decoy database peptides. Scaffold outputs label-free quantification based on precursor ion intensity for data from Proteome Discoverer. Precursor intensity refers to the area under an MS1 spectrum peak corresponding to a specific peptide. We used normalized total precursor intensity to derive quantitative values in this paper. Statistical analysis was performed by Qlucore Omics Explorer (Qlucore AB, Lund, Sweden). Two group comparisons (a paired t-test) was used to compare the mean value of relative abundance based on normalized total precursor intensity from three biological replicates for each protein identified in conditioned media collected in day 2 and day 10. The heatmap was generated based on hierarchical clustering of global protein expression filtered by the p-value (p < 0.05).
Cell growth inhibition assay by MTT method
Cellular toxicity to drugs was measured by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) method or CCK-8 (Dojindo Molecular Technologies, Inc., Rockville, MD) method following manufacturer’s instructions.
Generation of shFN1 and shFN2 stable cell lines
Plasmids encoding FN knockdown shRNAs were isolated from Mission shRNA Bacteria Glycerol Stocks NM_002026/TRCN0000293839 and NM_002026/TRCN0000293840 (designated shFN1 and shFN2, respectively). MISSION® pLKO.1-puro Non-Mammalian shRNA control plasmid (SCH002, Sigma) was amplified in MAX Efficiency® DH5α™ Competent Cells (Invitrogen) for 16 h at 30 oC. Plasmids were extracted from ampicillin-supplemented LB liquid cultures amplified from single colonies over 16 h at 30 oC using Qiagen Plasmid Midi Kit. Individual plasmids were co-transfected with lentiviral packaging plasmids (Invitrogen) into 293FT cells by Fugene6 Transfection Reagent (Roche, Basel, Switzerland). Viral supernatant was harvested after 48 and 72 h and concentrated by ultracentrifugation at 26,000 rpm through a 20 % sucrose gradient.
Lentiviral transduction
Melanoma cells were transduced with virus using ExpressMag Transduction System (Sigma). Briefly, viral supernatant was incubated with magnetic beads at room temperature for 15 min, added to the adherent cells and placed on a strong magnetic plate at 37 oC for 12 min. Media was replenished 16 h later and the viral mixture disposed in compliance with NIH policy. Transduced cells were selected with 2 μg/ml puromyocin (InvivoGen, San Diego, CA).
Immunofluorescence
For examination of 2D culture, cells were seeded directly onto glass chambers with a coverslip-bottomed no. 1.0, (Nalge, Nunc) according to previously described methods [
25]. For 3D interrogation, samples were prepared as previously described [
25]. Samples were rinsed twice with PBS, fixed with 4 % paraformaldehyde solution for 20 min, permeabilized with 0.5 % Triton X-100 for 20 min and rinsed and blocked in 5 % horse serum for 1 h at room temperature. Cells were then incubated with anti-FN1 antibody (1:100) and anti-actin antibody (1:100) for 12 h at 4 °C in 5 % horse serum. After incubation with primary antibody, cells were rinsed three times with PBS and then incubated with secondary antibodies (1:200) for 2 h at 4 °C. Cell nuclei were stained with DAPI (Sigma). Images were acquired with an upright Zeiss LSM 780 Meta confocal microscope (Zeiss, Jena, Germany).
Imaging specifications
One-photon, confocal, 2-dimensional images of 512 × 512 pixels (lateral dimensions) were acquired with a 1.4 NA 40 × oil-immersion objective. We sequentially excited our sample with the 405 nm, 488 nm lines from an argon ion laser with a power of < 3 % (total power 30 mW) and 546 nm from a solid-state laser (power of < 10 %). A secondary dichroic mirror, SDM 560, was employed in the emission pathway to delineate the red (band-pass filters 560–575 nm) and green (band-pass filters 505–525 nm) and blue channels (480-495 nm) at a gain of 400 on the amplifier. The laser power for the 543 nm setting was set at < 3 % of the maximum power and the gain on the detectors was set to 450.
3D soft agar assay
Anchorage-independent proliferation was quantified by soft agar assay. Cells were suspended in 1 mL of 0.36 % (w/v) bacto-agar (BD Biosciences) overlaid by a 0.6 % (w/v) bacto-agar support in 6-well plates in triplicates at densities of 5 × 103 cells per well for A375, A375.S2, A375Scr, A375 shFN2, A375.S2 Scr, A375.S2 shFN2 lines, respectively. Plates were incubated at 37 °C in normoxic conditions. Pathway inhibitors were used at the following concentrations: 3.0 μM cisplatin (DNA-crosslinking agent), 3.0 μM VX-11e (ERK inhibitor), 3.0 μM vemurafenib (BRAFV600E inhibitor) (Chemietek, Indianapolis, IN), and 50 nM paclitaxel (microtubule stabilizing agent) (Life Technologies). Pathway inhibitors were administered at the beginning of the experiment or initiated 14 days later. At the end of the experiment, wells were stained with 0.5 μg/mL of nitrotetrazolium blue chloride (Sigma-Aldrich). Colonies with > 20 μm in diameter were counted using the Bioreader Software and a BioSys BioCount 4000 Pro machine. Clonogenic survival for each line and condition was plotted as frequency of colony size normalized to a gaussian distribution. Experiments were performed in triplicate.
Discussion
Treatment strategies for metastatic malignant melanoma have significantly improved due to our current understanding of the molecular basis of tumor etiology [
29]. Targeted therapy based on BRAF V600E status has yielded dramatic results and disease regression has been observed. In spite of recent progress, the stark reality is that current treatments do not yet achieve durable responses due to melanoma intratumoral heterogeneity. The remodeling of the ECM results in changes within the microenvironment adding further complexity to the determinants of drug efficacy and the likelihood of acquired resistance. We present a novel mechanism by which cells tune their ECM secretion, namely FN via p38 MAPK –β1 integrin, in response to pharmaceutical inhibition of the MAPK signaling pathway in cutaneous melanoma cell lines, especially in 3D culture system. Here we show that when FN biogenesis is impaired, increased TNC expression is observed, suggesting a compensatory mechanism to attenuate drug treatment. By using the A375 cell lines that mimic tumor heterogeneity, we determined that only clones that can modulate FN biogenesis survive pharmaceutical intervention. These results, in conjunction with similar observations in patient data, suggest a role for ECM biosynthesis in the emergence of
de novo resistance.
Extracellular matrix proteins (ECMs) are often observed to be abundantly expressed by tumor cells in comparison to their normal counterparts. Analysis of patient data confirmed that overexpression of ECM proteins such as FN and TNC are likewise observed in patients that had acquired
de novo resistance from initial drug therapies. Similar outcomes have been noted for breast, laryngeal, urothelial and non-small-cell lung cancers [
22,
30‐
32]. Using proteomics and immunofluorescence, we determined a distinct temporal distribution of secreted ECM components and visualized the assembled ECM scaffold for two isogenic malignant melanoma clones. We determined that melanoma cells modulate the secretion of many ECM proteins that are also implicated as potential biomarkers for patients suffering from metastatic disease [
33]. Recently, ECM signatures were assigned to breast and ovarian tumors of differing metastatic potential [
34,
35]. These ECM signatures were not solely derived from the stromal cell secretions, but also included contributions from the tumor cells themselves [
35]. Here, we go a step further to follow the evolution of a melanoma-derived ECM signature. In particular, the secretion patterns of the two clones were significantly different with respect to relative amounts of FN, periostin, TNC, laminins and vitronectin (Fig.
1c). FN also differed architecturally; fibrils were predominantly observed in one clone vs. globular scaffolds for the other (Fig.
2d). FN fibril assembly is regulated by tensional reorganization of actin via stress fibers for cells cultured in 2D [
36‐
38]. Actin structures convey different mechanical properties based on spatial organization in 2D, and regulate specific motilities in 3D [
25,
39]. Furthermore, cell motility regulates ECM remodeling and plays a role in the final architecture of the ECM scaffold [
40]. These two cell lines show differential adhesion forces when placed in a 2D biomimetic platform simulating cell-ECM interactions [
41]. Additionally, differences in FN conformation dictate the availability of binding sites that affect signaling cascades associated with growth, migration and adhesion [
42,
43]. In our system, it remains to be seen if there is a difference in tensional regulation and whether globular vs. fibril conformations show differential drug sensitivity.
In this study, we observed that FN was differentially secreted and assembled when tumor cells harboring the BRAF
V600E mutation were cultured in 2D vs. in a biomimetic 3D platform [
44]. In vivo, tumor cells have access to various sources of fibronectin, namely the plasma and stroma. As a surrogate basement membrane gel, the laminin-rich ECM contains several ECM proteins and cytokines, including minute amounts of FN [
40], However, previous studies have shown that FN-null cells poorly assemble FN fibrils when exogenous FN is added to them [
45]. We confirmed that a reduced number of shFN cells assembled exogenous FN compared to Scr cells in in vivo and in vitro 3D culture (Figs.
3 and
7). Growth inhibition when FN has been compromised has also been observed for other types of cancer [
46]. This was due in part to reduced expression of β1 integrin and alterations of the cell cycle; however, in our system the short hairpin did not alter the cell cycle or reduce β1 integrin levels. Melanoma-derived conditioned media was shown to stimulate in vivo FN expression in target organs preceding future metastatic lesions. This phenomenon was also attributed to resident fibroblasts that create the “pre-metastatic niche” [
47]. Our data suggests that metastatic melanoma also modulates its “tumor niche” by secreting and assembling its own ECM scaffold to survive drug treatment. Our results suggest that modulation of FN secretion serves as a response to external stress and may be separate from the remodeling of stromal components observed during initial malignant transformation.
Melanoma is largely resistant to platinum treatments since several factors such as drug uptake, increased efflux, extracellular interaction via cell adhesions and slow cycling cells may contribute to intrinsic resistance [
48‐
50]. In our system 3D architecture did mitigate drug efficacy, as only a partial killing was achieved for FN-null tumor aggregates and minimal FN secretion was observed in response to cisplatin.
It has been previously reported that activation of the ERK/MAP kinase in melanoma cells stimulates FN biogenesis via the early growth response-1 transcription factor (Egr-1) [
51]. High FN and Egr-1 levels were found in BRAF
V600E mutant cells and patient tumors. However, stimulation of the ERK pathway was insufficient to induce FN biogenesis in normal melanocytes [
51]. Here, inhibition of the ERK pathway activates FN biogenesis via p38MAPK and β1 integrin signaling in melanoma cells but not in melanocytes. In a previous study, β1 integrin inhibition targeting FN has increased radio sensitization of breast tumor cells in 3D culture [
52]. However, non-malignant breast cells undergo apoptosis following treatment with a β1-integrin function-blocking antibody, whereas the malignant counterpart cells appear resistant to this treatment [
53,
54]. Integrin blocking treatment is successful only if there is a differential response between normal tissue and its malignant counterpart. Thus, in addition to multiple targets of MAPK signaling, concomitant treatment with a p38 inhibitor may be a better strategy to prevent acquire drug resistance due to FN biosynthesis. However, in the case of metastatic disease, acute treatment with integrin-blocking antibodies may be useful to overcome
de novo resistance. Nevertheless, alternative strategies to overcome FN mediated cell adhesion mediated drug resistance have been reported that could reverse drug resistance in leukemia and solid tumors [
55,
56].
In normal cells during early embryogenesis, FN provides a scaffold for the assembly of other ECM proteins to direct organ specificity and fate, so we reasoned that other ECM proteins would be altered when FN biogenesis is affected [
57]. In fact, we observed an increase in Tenascin-C biogenesis by shFN melanoma cells. Here, we show that drug treatment may induce ECM biosynthesis, contributing to
de novo resistance. This must be considered when designing therapeutic interventions. Our findings suggest that modulation of tumor ECM biogenesis mimics the behavior of bacteria that assemble a biofilm in response to nutrient deficiencies, antibiotics and oxidative stress [
58]. This biofilm acts as a physical barrier and signaling reservoir to communicate sensing of deleterious conditions. Tumor cells may use this secreted “biofilm” to communicate and communally enter a state of dormancy until environmental conditions are more favorable. If we can understand the mechanisms underlying tumor biofilm assembly, we may be able to seize a novel opportunity for therapeutic intervention.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
AA, AD, EC, HT, KF, WV, YK, BB, BBusby, and KT performed experiments and data analysis. AA, AD, EC, HT, KF, and KT wrote the main manuscript text, AA, AD, KF, and KT prepared figures. All authors read, reviewed and approved the final manuscript.